Quantum Computing Threat Looms

The core threat stems from Shor's Algorithm, developed in 1994, which can efficiently factor large numbers—the mathematical foundation of current RSA and ECC encryption. A sufficiently powerful quantum computer could use this algorithm to break today's standard encryption in hours or minutes, a task that would take classical computers thousands of years. This vulnerability has triggered a "harvest now, decrypt later" strategy, where adversaries are already collecting encrypted data from high-value targets like biotech and pharmaceutical companies. The goal is to stockpile this sensitive information—including proprietary drug formulas, clinical trial data, and manufacturing processes—with the intent of decrypting it once a cryptographically relevant quantum computer (CRQC) is available. In response, the U.S. National Institute of Standards and Technology (NIST) has been leading a multi-year process to standardize quantum-resistant cryptographic algorithms. After several rounds of evaluation, NIST finalized the first three post-quantum cryptography (PQC) standards in August 2024, including ML-KEM for general encryption and ML-DSA and SLH-DSA for digital signatures. The timeline for this transition is becoming concrete. NIST has outlined a plan to deprecate quantum-vulnerable algorithms by 2035, with some high-risk systems needing to transition much sooner. This is critical for the biomanufacturing sector, where data integrity is essential for GMP compliance and protecting intellectual property that has a long lifecycle. For gene therapy CDMOs and other biotechs, the quantum threat extends beyond data theft to operational integrity. Compromised digital systems could disrupt manufacturing processes, undermine electronic batch records, and jeopardize the validity of data used in regulatory filings and for digital twins in process optimization. The race to build a CRQC is accelerating, with multiple vendors claiming they will have such machines before 2030. While current quantum processors are not yet powerful enough to break real-world encryption, the rapid pace of development has made quantum readiness a strategic necessity, not a future concern. The biotech industry is a prime target due to its valuable intellectual property and reliance on complex, interconnected digital systems for R&D and manufacturing. Past cyberattacks on companies like Bayer and Moderna demonstrate the sector's vulnerability to espionage and data breaches, a risk that quantum computing will exponentially increase. Transitioning to post-quantum standards presents significant challenges, including the need for "crypto-agility"—the ability to update cryptographic algorithms without major system overhauls. In the near term, many organizations are expected to adopt hybrid approaches, combining classical and post-quantum algorithms to ensure security during the migration period.